Use of Erdafitinib in FGFR3-Mutated Recurrent Respiratory Papillomatosis

JCO Precis Oncol. 2022 Nov:6:e2200435. doi: 10.1200/PO.22.00435.
No abstract available

MeSH terms

  • Humans
  • Papillomavirus Infections*
  • Quinoxalines
  • Receptor, Fibroblast Growth Factor, Type 3 / genetics
  • Respiratory Tract Infections* / drug therapy

Substances

  • erdafitinib
  • Quinoxalines
  • FGFR3 protein, human
  • Receptor, Fibroblast Growth Factor, Type 3

Supplementary concepts

  • Recurrent respiratory papillomatosis